• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Results of the IELSG32 trial at a median follow-up of 88 months demonstrate that matrix followed by autologous transplant is associated with excellent survival and neurotolerability in patients with primary CNS lymphoma

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Calimeri, T.
    Cwynarski, K.
    Pulczynski, E.
    Fox, C. P.
    Schorb, E.
    Steffanoni, S.
    Foppoli, M.
    Celico, C.
    Falautano, M.
    Nonis, A.
    La Rosee, P.
    Binder, M.
    Fabbri, A.
    Ilariucci, F.
    Krampera, M.
    Roth, A.
    Hemmaway, C.
    Johnson, P. W.
    Linton, Kim M
    Pukrop, T.
    Gorlov, J.
    Balzarotti, M.
    Hess, G.
    Keller, U.
    Stilgenbauer, S.
    Panse, J.
    Tucci, A.
    Orsucci, L.
    Pisani, F.
    Zanni, M.
    Krause, S. W.
    Schmoll, H. J.
    Hertenstein, B.
    Rummel, M.
    Smith, J.
    Thurner, L.
    Cabras, G.
    Pennese, E.
    Ponzoni, M.
    Deckert, M.
    Politi, L. S.
    Finke, J.
    Ferranti, A.
    Cozens, K.
    Burger, E.
    Ielmini, N.
    Cavalli, F.
    Zucca, E.
    Illerhaus, G.
    Ferreri, A. J. M.
    Show allShow less
    Affiliation
    Lymphoma Unit, Department of Onco-Hematology ,IRCCS SanRaffaele Scientific Institute ,Milan, Italy;
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Introduction: The MATRix regimen (methotrexate, cytarabine, thiotepa, rituximab) significantly improved outcome of pts with primary CNS lymphoma (PCNSL) enrolled in the IELSG32 trial. At a median follow-up of 40 months, both whole-brain irradiation (WBRT) and autologous transplantation (ASCT) were safe and equally effective. However, sound assessment of OS, late complications, incidence of secondary tumors, and cognitive impairment requires longer follow-up. Herein, we report the results of IELSG32 trial at a median follow-up of 88 (IQR 77- 99) months. Methods: pts with untreated PCNSL (18-70 years) were randomly as signed to methotrexate-cytarabine (arm A), or arm A + rituximab (arm B), or arm B + thiotepa (MATRix; arm C). A second randomization assigned pts with responsive/stable disease after induction to WBRT (arm D) or BCNU-Thiotepa-conditioning ASCT (arm E). Treatment effect on cognitive functions and quality of life (QoL) were addressed by IPCG tests panel and EORTC-QLQ. Results: 219 pts were randomized (arm A 75; B 69; C 75). After induction, 167 had responsive/stable disease: 118 were assigned to WBRT (59) or ASCT (59) while 49 were excluded from 2nd randomization. Fifteen pts died of iatrogenic toxicity; 87 (40%) pts remain relapse-free (A 17; B 28; C 42), 14 of them died of unrelated causes (Table 1). Among 117 relapsing pts, 96 died of PCNSL, 7 of salvage therapy complications. Eight pts developed second cancers at 48-96 months from WBRT (5) or ASCT (3). Second tumors and deaths in relapse-free pts or during salvage were not significantly related to treatments (Table 1). Neuropsychological tests showed a significant impairment in attentiveness and executive functions in the WBRT arm, while transplanted pts had a significant improvement in these functions as well as memory and QoL. Pts treated with MATRix showed significantly better PFS (7-year: 20% arm A; 29% arm B; 52% arm C) and OS (7-year: 26% arm A; 37% arm B; 56% arm C). No significant differences were seen between the consolidation arms for either PFS (7-yr: 55% arm D; 50% arm E) or OS (7- yr: 63% vs 57%). Pts treated with MATRix and consolidation had a 7-yr OS of 70%, without a difference between WBRT and ASCT. Conclusions: MATRix was linked to excellent long-lasting outcome. WBRT and ASCT have comparable efficacy. MATRix and ASCT did not result in higher non-relapse mortality or second tumors onset. WBRT led to impairment of specific cognitive functions.
    Citation
    Calimeri T, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Steffanoni S, et al. RESULTS OF THE IELSG32 TRIAL AT A MEDIAN FOLLOW-UP OF 88 MONTHS DEMONSTRATE THAT MATRIX FOLLOWED BY AUTOLOGOUS TRANSPLANT IS ASSOCIATED WITH EXCELLENT SURVIVAL AND NEUROTOLERABILITY IN PATIENTS WITH PRIMARY CNS LYMPHOMA. Haematologica. 2021;106(10):33-.
    Journal
    Haematologica
    URI
    http://hdl.handle.net/10541/624914
    Type
    Meetings and Proceedings
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.